Immunohistochemical Assessment of PTEN Expression: A Possible Tool to Screen Premalignant Endometrial Lesions
Paper Details
Immunohistochemical Assessment of PTEN Expression: A Possible Tool to Screen Premalignant Endometrial Lesions
Abstract
This study was carried out to observe the PTEN Expression in normal, hyperplastic and neoplastic endometrial tissues using Immunohistochemistry (IHC). In the present study, PTEN expression was assessed in 75 endometrial biopsies by using immunohistochemistry (IHC). Histopathologically, there were 15 cases of normal endometrium, 24 cases of simple hyperplasia, 22 cases of complex hyperplasia and 14 cases of endometrial carcinoma. PTEN proportionate score (PS) was +2 in all cases of the normal endometrium, +2 in 36, +1 in 6 and 0 in 4 cases of endometrial hyperplasia, +2 in 4, +1 in 4 and 0 in 4 cases of complex hyperplasia without atypia and +2 in 2, +1 in 3 and 0 in 9 cases of endometrial carcinoma. SPSS 21 was used for analyzing the data. A highly significant difference of PTEN PS (p < .001) was among these groups of endometrial lesions. It is concluded that there is a close association between loss of PTEN expression and malignant transformation. Therefore, PTEN expression assessed by immunohistochemistry (IHC) can be used as a possible tool to screen premalignant endometrial lesions.
Ayala EG, Mastrascusa LC, Martínez DS, Anaya HM. 2010. Hiperplasia endometrial: analisis de serie de casos diagnosticados en biopsia endometrial. Revista Chilena De Obstetricia Y Ginecolgia 75(3), 146-152. http://dx.doi.org/10.4067/S071775262010000300002
Cristofano AD, Ellenson LH. 2007. Endometrial carcinoma. Annual Review of Pathology 2, 57-85. https://dx.doi.org/10.1146/annurev.pathol.2.010506.091905
Djordjevic B, Henessy BT, Li J, Barkoh BA, Luthra R, Mills GB, Broaddus RR. 2012. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Modern Pathology 25(5), 699-708. https://dx.doi.org/10.1038/modpathol.2011.208
Gamble M. 2008. The hemtoxylins and eosin. In: Theory and practice of histological techniques (Eds. Bancroft JD and Gamble M.). 6th Edition. Elsevier P 121-134. http://dx.doi.org/10.1016/B978-0-443-10279-0.50016-6
Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B. 2012. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. International Journal of Gynecological Pathology 31(1), 48-56. https://dx.doi.org/10.1097/PGP.0b013e3182230d00
Garg K, Soslow RA. 2014. Endometrial carcinoma in women aged 40 years and younger. Archives of Pathology and Laboratory Medicine 138(3), 335-342. https://dx.doi.org/10.5858/arpa.2012-0654-RA
Kapucuoglu N, Aktepe F, Kaya H, Bircan S, Karahan N, Ciriş M. 2007. Immunohistochemical expression of PTEN in normal, hypeplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index. Pathology, Research and Practice 203(3), 153-162. https://dx.doi.org/10.1016/j.prp.2007.01.003
Kiechle M, Hinrichs M, Jacobsen A, Lüttges J, Pfisterer J, Kommoss F, Arnold N. 2000. Genetic imbalances in precursor lesions of endometrial cancer detected by comparative genomic hybridization. The American Journal of Pathology 156(6), 1827-1833. https://dx.doi.org/10.1016/S0002-9440(10)65055-9
Kurman RJ, Mazur MT. 1994. Benign diseases of the endometrium. In: Blaustein’s pathology of the female genital tract (Ed. Kurman RJ.). 4th Edition. Springer-Verlag New York. P 367-410. https://dx.doi.org/10.1007/978-1-4757-3889-6_10
Lee H, Choi HJ, Kang CS, Lee HJ, Lee WS, Park CS. 2012. Expression of miRNAs and PTEN in endometrial specimens ranging from histologically normal to hyperplasia and endometrial adenocarcinoma. Modern Pathology 25(11), 1508-1515. https://dx.doi.org/10.1038/modpathol.2012.111
Mutter GL, Baak JP, Crum CP, Richart RM, Ferenczy A, Faquin WC. 2000. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. The Journal of Pathology 190(4), 462–469. https://dx.doi.org/10.1002/(sici)1096-9896(200003)190:4<462::aid-path590>3.0.co;2-d
Mutter GL. 2002. Diagnosis of premalignant endometrial disease. Journal of Clinical Pathology 55(5), 326-331.
Orbo A, Vereide A, Arnes M, Pettersen I, Straume B. 2014. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG-An International Journal of Obstetrics and Gynaecology 121(4), 477-486. http://dx.doi.org/10.1111/1471-0528.12499
Pallares J, Bussaglia E, Martínez-Guitarte JL, Dolcet X, Llobet D, Rue M, Sanchez-Verde L, Palacios J, Prat J, Matias-Guiu X. 2005. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Modern Pathology 18, 719-727. https://dx.doi.org/10.1038/modpathol.3800347
Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, Berchuck A. 1998. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clinical Cancer Research 4, 3005-3010.
Romano C, Schepis C. 2012. PTEN gene: A model for genetic diseases in dermatology. The Scientific World Journal 2012, 1-8. https://dx.doi.org/10.1100/2012/252457
Rosai J, Ackerman LV. 2011. Gross techniques in surgical pathology. In: PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics (Eds. Housten M and Scott J.). 10th Edition. Edinburg. Elsevier p 25-30.
Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bo TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kallan KH, Meyerson M, Akslen LA, Beroukhim R. 2009. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America 106(12), 4834-4839. https://dx.doi.org/10.1073/pnas.0806514106
Samulak D, Grosman-Dziewiszek P, Michalska MM, Mojs E, Samulak K, Romanowicz H, Smolarz B. 2013. Evaluation of expression of the PTEN gene, oestrogen and progesterone receptors as diagnostic and predictive factors in endometrial cancer. Pathology Oncology Research 20(1), 191-196. http://dx.doi.org/10.1007/s12253-013-9684-3
Sarmadi S, Izadi-Mood N, Sotoudeh K, Tavangar SM. 2009. Altered PTEN expression; a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium. Diagnostic Pathology 4, 41-46. https://dx.doi.org/10.1186/1746-1596-4-41
Shawana S, Kehar SI, Shaikh F. 2014. Differential expression of phosphatase and tensin homologue in normal, hyperplastic and neoplastic endometrium. The Journal of the Pakistan Medical Association 64(10), 1103-1108.
Spenceer LT, Bancroft JD. 2008. Tissue processing. In: Theory and practice of histological techniques (Eds. Bancroft JD and Gamble M.). 6th Edition. Elsevier, p 90-92.
Sun H, Enomoto T, Shroyer KR, Ozaki K, Fujita M, Ueda Y, Nakashima R, Kuragaki C, Ueda G, Murata Y. 2002. Clonal analysis and mutations in the PTEN and the K-ras genes in endometrial hyperplasia. Diagnostic Molecular Pathology 11(4), 204-211. http://dx.doi.org/10.1097/00019606-200212000-00003
Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S. 2008. Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma. Journal of the Medical Association of Thailand 91(8), 1161-1165.
Yevgeniya J, Chiappinelli KB, Mutch DG, Zighelboim I, Goodfellow PJ. 2012. Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis? Gynecologic Oncology 124(2), 340-346. https://dx.doi.org/10.1016/j.ygyno.2011.10.011
Umer Farooq, Wajiha Khalid, Saba Shamim, 2021. Immunohistochemical Assessment of PTEN Expression: A Possible Tool to Screen Premalignant Endometrial Lesions. Int. J. Biosci., 18(2), 186-193.
Copyright © 2021 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.